Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a nationwide analysis.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
05 Mar 2024
Historique:
received: 29 06 2023
revised: 01 12 2023
accepted: 21 01 2024
medline: 7 3 2024
pubmed: 7 3 2024
entrez: 6 3 2024
Statut: aheadofprint

Résumé

Postoperative pancreatic fistula remains the leading cause of significant morbidity after pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Preoperative chemoradiotherapy has been described to reduce the risk of postoperative pancreatic fistula, but randomized trials on neoadjuvant treatment in pancreatic ductal adenocarcinoma focus increasingly on preoperative chemotherapy rather than preoperative chemoradiotherapy. This study aimed to investigate the impact of preoperative chemotherapy and preoperative chemoradiotherapy on postoperative pancreatic fistula and other pancreatic-specific surgery related complications on a nationwide level. All patients after pancreatoduodenectomy for pancreatic ductal adenocarcinoma were included in the mandatory nationwide prospective Dutch Pancreatic Cancer Audit (2014-2020). Baseline and treatment characteristics were compared between immediate surgery, preoperative chemotherapy, and preoperative chemoradiotherapy. The relationship between preoperative chemotherapy, chemoradiotherapy, and clinically relevant postoperative pancreatic fistula (International Study Group of Pancreatic Surgery grade B/C) was investigated using multivariable logistic regression analyses. Overall, 2,019 patients after pancreatoduodenectomy for pancreatic ductal adenocarcinoma were included, of whom 1,678 underwent immediate surgery (83.1%), 192 (9.5%) received preoperative chemotherapy, and 149 (7.4%) received preoperative chemoradiotherapy. Postoperative pancreatic fistula occurred in 8.3% of patients after immediate surgery, 4.2% after preoperative chemotherapy, and 2.0% after preoperative chemoradiotherapy (P = .004). In multivariable analysis, the use of preoperative chemoradiotherapy was associated with reduced risk of postoperative pancreatic fistula (odds ratio, 0.21; 95% confidence interval, 0.03-0.69; P = .033) compared with immediate surgery, whereas preoperative chemotherapy was not (odds ratio, 0.59; 95% confidence interval, 0.25-1.25; P = .199). Intraoperatively hard, or fibrotic pancreatic texture was most frequently observed after preoperative chemoradiotherapy (53% immediate surgery, 62% preoperative chemotherapy, 77% preoperative chemoradiotherapy, P < .001). This nationwide analysis demonstrated that in patients undergoing pancreatoduodenectomy for pancreatic ductal adenocarcinoma, only preoperative chemoradiotherapy, but not preoperative chemotherapy, was associated with a reduced risk of postoperative pancreatic fistula.

Sections du résumé

BACKGROUND BACKGROUND
Postoperative pancreatic fistula remains the leading cause of significant morbidity after pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Preoperative chemoradiotherapy has been described to reduce the risk of postoperative pancreatic fistula, but randomized trials on neoadjuvant treatment in pancreatic ductal adenocarcinoma focus increasingly on preoperative chemotherapy rather than preoperative chemoradiotherapy. This study aimed to investigate the impact of preoperative chemotherapy and preoperative chemoradiotherapy on postoperative pancreatic fistula and other pancreatic-specific surgery related complications on a nationwide level.
METHODS METHODS
All patients after pancreatoduodenectomy for pancreatic ductal adenocarcinoma were included in the mandatory nationwide prospective Dutch Pancreatic Cancer Audit (2014-2020). Baseline and treatment characteristics were compared between immediate surgery, preoperative chemotherapy, and preoperative chemoradiotherapy. The relationship between preoperative chemotherapy, chemoradiotherapy, and clinically relevant postoperative pancreatic fistula (International Study Group of Pancreatic Surgery grade B/C) was investigated using multivariable logistic regression analyses.
RESULTS RESULTS
Overall, 2,019 patients after pancreatoduodenectomy for pancreatic ductal adenocarcinoma were included, of whom 1,678 underwent immediate surgery (83.1%), 192 (9.5%) received preoperative chemotherapy, and 149 (7.4%) received preoperative chemoradiotherapy. Postoperative pancreatic fistula occurred in 8.3% of patients after immediate surgery, 4.2% after preoperative chemotherapy, and 2.0% after preoperative chemoradiotherapy (P = .004). In multivariable analysis, the use of preoperative chemoradiotherapy was associated with reduced risk of postoperative pancreatic fistula (odds ratio, 0.21; 95% confidence interval, 0.03-0.69; P = .033) compared with immediate surgery, whereas preoperative chemotherapy was not (odds ratio, 0.59; 95% confidence interval, 0.25-1.25; P = .199). Intraoperatively hard, or fibrotic pancreatic texture was most frequently observed after preoperative chemoradiotherapy (53% immediate surgery, 62% preoperative chemotherapy, 77% preoperative chemoradiotherapy, P < .001).
CONCLUSION CONCLUSIONS
This nationwide analysis demonstrated that in patients undergoing pancreatoduodenectomy for pancreatic ductal adenocarcinoma, only preoperative chemoradiotherapy, but not preoperative chemotherapy, was associated with a reduced risk of postoperative pancreatic fistula.

Identifiants

pubmed: 38448277
pii: S0039-6060(24)00055-2
doi: 10.1016/j.surg.2024.01.029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Leonoor V Wismans (LV)

Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.

J Annelie Suurmeijer (JA)

Department of Surgery, Amsterdam UMC, location University of Amsterdam, the Netherlands; Cancer Center Amsterdam, the Netherlands.

Jelle C van Dongen (JC)

Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.

Bert A Bonsing (BA)

Department of Surgery, Leiden University Medical Center, the Netherlands.

Hjalmar C Van Santvoort (HC)

Department of Surgery, Regional Academic Cancer Center Utrecht, St Antonius Hospital Nieuwegein, the Netherlands.

Johanna W Wilmink (JW)

Cancer Center Amsterdam, the Netherlands; Department of Medical Oncology, Amsterdam UMC, location University of Amsterdam, the Netherlands.

Geertjan van Tienhoven (G)

Cancer Center Amsterdam, the Netherlands; Department of Radiation Oncology, Amsterdam UMC, location University of Amsterdam, the Netherlands.

Ignace H de Hingh (IH)

Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.

Daan J Lips (DJ)

Department of Surgery, Medisch Spectrum Twente, Enschede, the Netherlands.

Erwin van der Harst (E)

Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands.

Vincent E de Meijer (VE)

Department of Surgery, University of Groningen, University Medical Center Groningen, the Netherlands.

Gijs A Patijn (GA)

Department of Surgery, Isala Clinics, Zwolle, the Netherlands.

Koop Bosscha (K)

Department of Surgery, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands.

Martijn W Stommel (MW)

Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

Sebastiaan Festen (S)

Department of Surgery, OLVG, Amsterdam, the Netherlands.

Marcel den Dulk (M)

Department of Surgery, Maastricht University Medical Center, the Netherlands.

Joost J Nuyttens (JJ)

Department of Radiation Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Martijn P W Intven (MPW)

Department of Radiation Oncology, University Medical Center Utrecht, the Netherlands.

Judith de Vos-Geelen (J)

Department of Medical Oncology, Maastricht University Medical Center, the Netherlands.

I Quintus Molenaar (IQ)

Department of Surgery, Regional Academic Cancer Center Utrecht, St Antonius Hospital Nieuwegein, the Netherlands.

Olivier R Busch (OR)

Department of Surgery, Amsterdam UMC, location University of Amsterdam, the Netherlands; Cancer Center Amsterdam, the Netherlands.

Bas Groot Koerkamp (BG)

Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.

Marc G Besselink (MG)

Department of Surgery, Amsterdam UMC, location University of Amsterdam, the Netherlands; Cancer Center Amsterdam, the Netherlands. Electronic address: http://www.twitter.com/MarcBesselink.

Casper H J van Eijck (CHJ)

Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: c.vaneijck@erasmusmc.nl.

Classifications MeSH